Positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), unlock the next chapter in AstraZeneca's ambition to develop therapies that improve cardiometabolic and kidney health and reduce weight-related complications. These results, presented today at the 2026 Scientific Sessions of the American Diabetes Association (ADA) and simultaneously published in The Lancet, mark an important step in building AstraZeneca’s differentiated weight management portfolio of monotherapies and combinations, supported by the Company's broad CVRM pipeline and global commercial expertise. AstraZeneca is advancing elecoglipron into an extensive Phase III programme in obesity and type 2 diabetes, including cardiovascular and kidney outcome trials.

In VISTA (n=310), adults with obesity or overweight and at least one comorbidity receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint. Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo. The trial also met the dual primary endpoint of proportion of participants achieving at least 5% weight loss at 26 weeks, with up to 88.8% of participants receiving elecoglipron achieving this threshold. In addition, elecoglipron showed clinically meaningful improvements in several exploratory analyses of cardiometabolic risk factors including lower blood pressure and C-reactive protein levels, a marker of systemic inflammation.